In Depth | Jaydess: new low-dose intrauterine contraceptive

Bayer has launched Jaydess, a new low-dose levonorgestrel-containing intrauterine delivery system that can be used to provide long-acting reversible contraception for up to three years.

Jaydess is not first choice for contraception in nulliparous women.
Jaydess is not first choice for contraception in nulliparous women.
Jaydess (levonorgestrel 13.5mg) continuously releases a low dose of levonorgestrel and results in a lower systemic exposure to the drug than is observed with the other available levonorgestrel-containing intrauterine system (IUS), Mirena (levonorgestrel 52mg). Jaydess is effective for up to 3 years whereas Mirena is effective for up to 5 years. For both devices, removal of the system results in a rapid return to a woman's usual level of fertility.1


The use of levonorgestrel in contraception is well-established. Its effects are mediated primarily through local progestogenic activity in the uterine cavity. The high levonorgestrel concentration in the endometrium downregulates endometrial oestrogen and progesterone receptors, making the endometrium relatively insensitive to circulating estradiol and preventing proliferation. Thickening of the cervical mucus inhibits the passage of sperm through the cervical canal while the local milieu of the uterus and fallopian tubes inhibits sperm mobility and function, thereby preventing fertilisation.1


The efficacy of the levonorgestrel 13.5mg IUS (T-frame size 28mm x 30mm) was assessed in an open-label single-blind phase III study involving 1,432 parous and nulliparous women aged 18 to 35 years.2

The one-year and three-year Pearl Indices were 0.41 (95% CI 0.13-0.96) and 0.33 (95% CI 0.16-0.60), respectively, with an estimated cumulative failure rate over three years of 0.9%.2

Safety profile

Placement of the IUS was rated by investigators as easy in 90% of women and very difficult in 1% of women. The device was generally well tolerated with treatment-related serious adverse events reported by 0.6% of women.2

Spotting may occur during the first few months of using Jaydess. Thereafter, the strong suppression of the endometrium results in a reduced duration and volume of menstrual bleeding.1


  1. Jaydess Summary of Product Characteristics, April 2014.
  2. Nelson A et al. Obstet Gynecol 2013; 122: 1205-13.

View Jaydess drug record

Further information: Bayer

Follow MIMS on Twitter

Sign up for MIMS bulletins

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

A woman wearing a white vest as a blue-gloved hand of a healthcare professional are seen injecting a vaccine.

'Nocebo' effect may cause two-thirds of COVID-19 vaccine reactions, study suggests

Two-thirds of adverse reactions reported with the COVID-19...

An elderly woman with one arm in a plaster cast sits resting both hands on her walker

Doctors urge NICE to reverse decision on new osteoporosis drug

More than NHS 100 clinicians have called on NICE to...

Image of both strengths of Seffalair Spiromax inhaler side by side.

New salmeterol/fluticasone dry powder inhaler for asthma

Seffalair Spiromax is the sixth dry powder salmeterol/fluticasone...